Justia U.S. Federal Circuit Court of Appeals Opinion Summaries

This case concerns a dispute over the alleged infringement of a patent related to an insulated overhead door. Cold Chain, LLC owns U.S. Patent No. 9,151,084, and Ridge Corporation became its exclusive licensee in February 2023. Ridge alleged that Kirk NationaLease Co., Truck & Trailer Parts Solutions, Inc., and Altum LLC infringed claims of the patent by manufacturing and selling a roll-up door. Ridge also brought claims for patent inducement, contributory infringement, tortious interference with business relationships, and false patent marking. The accused product is constructed as a “sandwich” panel with two thermoplastic membranes surrounding a foam layer, which is modified to traverse curved tracks.The United States District Court for the Southern District of Ohio initially granted Ridge’s motion for a preliminary injunction, enjoining the defendants from certain activities related to the accused door. The United States Court of Appeals for the Federal Circuit vacated that injunction, finding Ridge lacked standing as it was not an exclusive licensee with all substantial rights. Ridge then amended its complaint, adding Cold Chain as a plaintiff, and the district court again granted a preliminary injunction, concluding the plaintiffs had a strong likelihood of success on the merits.Upon review, the United States Court of Appeals for the Federal Circuit reversed the district court’s order. The court held that the defendants raised substantial questions regarding whether the accused door met three distinct claim limitations: flexibility along the entire length, the foam forming the second outermost surface, and whether the door qualifies as an “insulated overhead door.” The court also found the plaintiffs failed to demonstrate irreparable harm. The preliminary injunction was therefore reversed and the case remanded for further proceedings. View "RIDGE CORP. v. KIRK NATIONALEASE CO. " on Justia Law

The matter concerns a patent covering methods for generating digital images using an external visual server, offloading intensive image processing from a client device to a server that generates, compresses, and transmits images back to the client for display. The patent’s claimed improvement over prior art is the complete transfer of visual processing to the external server, so that the client only handles user input and image decompression. Sony sought inter partes review of twelve claims in the patent, arguing they were obvious in light of prior art, particularly a patent (“Wiltshire”) that described a server-based gaming system transmitting compressed images to clients.Previously, the Patent Trial and Appeal Board (the Board) initially found the claims not unpatentable, concluding Wiltshire did not disclose “generating” images at the server as required by the claims. On Sony’s appeal, the United States Court of Appeals for the Federal Circuit vacated that decision, holding that Wiltshire did disclose generating new images at the server, especially since it referenced games such as Doom that require real-time image generation. The Federal Circuit remanded for further proceedings. On remand, the Board found that Wiltshire, in combination with another reference (“Saha”) disclosing MPEG compression, taught all claim limitations, including the necessary image compression and transmission steps, and held all challenged claims unpatentable as obvious.On appeal, the United States Court of Appeals for the Federal Circuit reviewed whether the Board had exceeded the scope of its mandate or lacked substantial evidence for its findings. The Federal Circuit held that the Board properly followed its mandate, did not improperly revisit issues, and that substantial evidence supported the Board’s finding that the prior art disclosed all elements of the challenged claims. The court affirmed the Board’s decision, holding the claims unpatentable as obvious. View "INTELLECTUAL PIXELS LIMITED v. SONY INTERACTIVE ENTERTAINMENT LLC " on Justia Law

The dispute centered on two patents owned by Wyeth that claim methods of treating non-small cell lung cancer (NSCLC) resistant to two specific drugs, gefitinib and erlotinib, by administering “irreversible” EGFR inhibitors. The patents require the daily administration of a “unit dosage” of an irreversible EGFR inhibitor that covalently binds to specific amino acids in the EGFR protein. The patent specifications list three example compounds, describe in vitro test results, and provide general dosage ranges. However, the specifications do not include any working examples of dosing regimens administered to human patients, nor do they explain how to reliably determine a therapeutically effective and safe dosage for such patients.In the United States District Court for the District of Delaware, Wyeth sued AstraZeneca for alleged infringement based on AstraZeneca’s marketing of an irreversible EGFR inhibitor. After a jury found in Wyeth’s favor, determining the asserted patent claims were not invalid and awarding damages, AstraZeneca renewed its motion for judgment as a matter of law (JMOL), arguing that the patents were invalid for lack of enablement. The district court granted JMOL, concluding that the patents did not provide sufficient guidance for a skilled artisan to determine a suitable daily unit dosage for patients without undue experimentation, especially given the evidence that some disclosed dosage ranges would be toxic in humans.The United States Court of Appeals for the Federal Circuit affirmed the district court’s judgment. The Federal Circuit held that the asserted claims were invalid for lack of enablement under 35 U.S.C. § 112(a). The court concluded that the patent specifications failed to teach skilled artisans how to determine, without undue experimentation, daily unit dosages that would be therapeutically effective and safe for patients across the full scope of the claimed compounds. View "WYETH LLC v. ASTRAZENECA PHARMACEUTICALS LP " on Justia Law

TrackTime, LLC owned two patents claiming methods and systems for navigating within multimedia files on a mobile device using a time-correlated transcript. The patents described creating a synchronization index that allows users to tap on text to play corresponding multimedia segments and to annotate and share transcripts. TrackTime sued Amazon.com Services LLC and Audible, Inc. for patent infringement in the United States District Court for the District of Delaware, asserting claims from both patents.In the District of Delaware, the court ruled on two sets of claims. For the ’978 patent, the court construed certain limitations as means-plus-function terms under 35 U.S.C. § 112(f) and found the claims indefinite due to insufficient structural disclosure in the specification, leading to a holding of invalidity. For the ’638 patent, a jury trial was held focusing on claim 9. The jury found claim 9 not infringed and invalid for anticipation, as well as for other grounds. TrackTime’s post-trial motions for judgment as a matter of law and for a new trial were denied. Final judgment was entered accordingly.The United States Court of Appeals for the Federal Circuit reviewed the case. For the ’978 patent, the court found that further analysis was needed regarding whether the “executable program code” limitations should be considered means-plus-function terms under § 112(f), especially in light of intervening precedent from Dyfan, LLC v. Target Corp. The court vacated the district court’s indefiniteness ruling and remanded for further proceedings. For the ’638 patent, the Federal Circuit affirmed the judgment of invalidity for anticipation, holding there was sufficient evidence for the jury to find claim 9 anticipated by LiveNote and affirming the denial of post-trial motions. The disposition was affirmed in part, vacated in part, and remanded. View "TRACKTIME, LLC v. AMAZON.COM SERVICES LLC " on Justia Law

Otsuka America Pharmaceutical and its subsidiary own a patent covering a method for treating pseudobulbar affect and emotional lability by administering dextromethorphan with quinidine. Their branded drug, Nuedexta, combines these substances in their salt forms. After the FDA approved Hetero Labs’ generic version, which uses identical salt forms and amounts, Hetero announced plans to launch its product. Otsuka responded by filing suit in the United States District Court for the District of Delaware, seeking a temporary restraining order and a preliminary injunction to block Hetero’s market entry.The District Court for the District of Delaware first issued a temporary restraining order, then granted a preliminary injunction, preventing Hetero from selling its generic drug. The court found Otsuka likely to succeed in proving patent infringement and determined that equitable factors favored the injunction. It also waived the requirement for Otsuka to post a bond pending appeal, citing strong equities in Otsuka’s favor.The United States Court of Appeals for the Federal Circuit reviewed the case. It affirmed the district court’s interpretation of the patent claim terms “dextromethorphan” and “quinidine” as including both the free base and salt forms administered to patients, rather than only the active moiety. This construction meant that Hetero’s generic product infringed the patent. The Federal Circuit also held that the district court acted within its discretion in granting the preliminary injunction. However, it vacated the district court’s waiver of the Rule 65(c) bond requirement, finding that such waivers are extremely rare in cases involving commercial activity, and remanded the issue for reconsideration. Thus, the preliminary injunction was affirmed but the bond waiver was vacated and remanded. View "OTSUKA AMERICA PHARMACEUTICAL, INC. v. HETERO LABS LIMITED " on Justia Law

Three property owners in Oregon alleged that the federal government committed a taking of their property rights under the Fifth Amendment when the Surface Transportation Board (STB) issued a Notice of Interim Trail Use or Abandonment (NITU) involving a railroad corridor that crossed their properties. The corridor, previously used for freight trains by the Port of Tillamook Bay Railroad (POTB), was also leased to the Oregon Coast Scenic Railroad (OCSR), which operated a scenic passenger-excursion service both before and after the NITU was issued. After severe storm damage in 2007, POTB ceased freight operations, but OCSR continued using the corridor under its lease, which extended at least until 2026.The United States Court of Federal Claims previously found that a taking had occurred due to the issuance of the NITU. The case then proceeded to a valuation phase to determine just compensation. The Court of Federal Claims ruled that the property owners did not meet their burden to prove that the NITU caused a reduction in the fair market value of their land. The court found that the “before” condition for valuation properly included OCSR’s ongoing operations, and that the property owners failed to show an actual market value loss resulting from the NITU and the new trail-use easement.On appeal, the United States Court of Appeals for the Federal Circuit affirmed the Court of Federal Claims’ judgment. The Federal Circuit held that the “before” condition for compensation must reflect the ongoing encumbrance of the scenic railroad’s operations, as the lease and use by OCSR would have existed regardless of the NITU. The court also concluded that the property owners had not proven with reasonable certainty any diminution in market value attributable to the NITU or the trail easement, and thus were not entitled to compensation. The judgment was affirmed. View "LOVERIDGE v. US " on Justia Law

This case centers on a contractor’s claim for a Type I differing site condition relating to a flood control project in Jefferson Parish, Louisiana. The United States Army Corps of Engineers issued a solicitation for work on the Trapp Canal, which included boring logs and cross-sections of the canal but lacked specific information about the southwest bank. Hamp’s Construction LLC, after being awarded the contract, encountered unexpected bank failures in the southwest quadrant, resulting in unsafe conditions for land-based equipment and significant delays. Hamp’s Construction submitted a request for equitable adjustment and later a formal claim, asserting that the conditions encountered were materially different from those indicated in the contract documents.The contracting officer denied Hamp’s Construction’s request and subsequent claim, concluding there was insufficient proof of a differing site condition under the relevant Federal Acquisition Regulation clause. Hamp’s Construction appealed to the Armed Services Board of Contract Appeals. After a hearing, the Board found that although Hamp’s Construction had faced unforeseen difficulties and increased costs, the contract documents did not provide representations or indications about the subsurface conditions of the southwest bank. The Board emphasized the absence of boring logs or explicit information for the area where the failures occurred and denied the appeal.The United States Court of Appeals for the Federal Circuit reviewed the Board’s legal conclusions de novo and factual findings for substantial evidence. The court held that, for a Type I differing site condition claim, the contract must affirmatively indicate conditions at the disputed site. The court determined that Hamp’s Construction could not reasonably rely on contract documents as indications for the southwest bank. The court affirmed the Board’s decision, holding that Hamp’s Construction failed to establish a threshold element of a Type I differing site condition claim. View "HAMP'S CONSTRUCTION LLC v. SECRETARY OF THE ARMY" on Justia Law

The case concerns an attorney who represented a veteran in seeking disability benefits from the Department of Veterans Affairs (VA). The veteran originally filed a claim in 2007 for a bilateral hip disability and received a rating in 2008, which was later increased. In 2018, the Board issued a final denial for a higher rating for the left hip, which was not appealed and thus became final. In 2021, after the veteran underwent left hip replacement surgery, the attorney assisted with a new claim, resulting in a significantly increased rating and an award of past-due benefits. The attorney sought fees from this award, arguing that her work fell within the statutory scheme permitting attorney’s fees for representation after notice of the agency’s initial decision.The Board of Veterans’ Appeals denied the attorney’s request for fees, reasoning that the December 2021 rating decision was the initial decision for the increased rating claim, and since the attorney had not performed compensable work after that decision, she was not entitled to fees under 38 U.S.C. § 5904(c)(1). The United States Court of Appeals for Veterans Claims affirmed, concluding that the September 2021 claim for increased compensation was a new claim, not part of the same “case” as the original 2007 claim, and thus the attorney’s work prior to the December 2021 decision was not compensable.The United States Court of Appeals for the Federal Circuit reviewed the matter de novo and affirmed the Veterans Court’s decision. The court held that, for purposes of attorney’s fees under § 5904(c)(1), a new claim for increased disability based on new evidence and circumstances is not part of the same “case” as the original claim. The attorney was not entitled to fees for work performed prior to the December 2021 rating decision. The judgment was affirmed. View "JACKSON v. COLLINS " on Justia Law

Enanta Pharmaceuticals owned a patent directed to certain chemical compounds and methods for inhibiting coronavirus replication. The patent claimed priority to an earlier provisional application filed in July 2020. In the original provisional application, the relevant chemical group was described as containing two to twelve carbon atoms, while in the later patent, the range was changed to include one to twelve carbon atoms. Before the non-provisional patent was filed, Pfizer publicly disclosed a compound that fell within the scope of Enanta’s later patent claims.Enanta filed suit in the United States District Court for the District of Massachusetts, asserting that Pfizer’s product infringed its patent. Pfizer countered that the patent was invalid because its public disclosure anticipated the patent claims, and argued that Enanta’s patent could not claim priority to the earlier provisional application since the specific chemical group was not adequately supported in the provisional filing. The district court granted summary judgment in Pfizer’s favor, concluding that the change from two to one carbon atoms was not a correctable typographical error, and that the patent could not claim the earlier priority date.On appeal, the United States Court of Appeals for the Federal Circuit reviewed the district court’s decision de novo. The appellate court held that the provisional application did not provide written description support for the later patent’s claims, specifically the inclusion of the one-carbon group, and thus the patent was not entitled to the earlier priority date. As a result, Pfizer’s disclosure anticipated all claims of Enanta’s patent, rendering them invalid. The Federal Circuit affirmed the district court’s grant of summary judgment. View "ENANTA PHARMACEUTICALS, INC. v. PFIZER INC. " on Justia Law

Elizabeth Jacobson, a former Wells Fargo mortgage loan officer, filed a whistleblower declaration with the U.S. Attorney General under the Financial Institutions Anti-Fraud Enforcement Act of 1990 (FIAFEA), alleging that Wells Fargo engaged in fraudulent origination of “stated income” loans between 2005 and 2007. The Department of Justice investigated and determined her declaration was deficient, citing the absence of new factual elements, her admitted participation in the alleged conduct, and that the allegations were already publicly disclosed. Subsequently, the government reached a substantial settlement with Wells Fargo over related allegations.Jacobson challenged the Attorney General’s determination in the United States Court of Federal Claims, arguing she was entitled to a share of the settlement under FIAFEA and asserting that the statutory bar on judicial review violated her due process rights. The government moved to dismiss the complaint for lack of subject-matter jurisdiction, invoking FIAFEA’s express provision precluding judicial review of the Attorney General’s actions except for failure to provide required notification. The Court of Federal Claims granted the motion, holding it lacked jurisdiction to review the Attorney General’s determinations regarding Jacobson’s eligibility for a whistleblower award. The court also rejected her constitutional argument, finding no jurisdiction under the Due Process Clause.On appeal, the United States Court of Appeals for the Federal Circuit affirmed the dismissal. The court held that FIAFEA’s statutory language provided a clear and convincing indication that Congress intended to bar judicial review of the Attorney General’s determinations regarding whistleblower declarations, except for notification failures not at issue in this case. The Federal Circuit also held that the lower court was not required to determine whether FIAFEA is money-mandating before dismissing for lack of jurisdiction and found no Tucker Act jurisdiction over Jacobson’s due process claim. View "JACOBSON v. US " on Justia Law